Printer Friendly

Research and Markets: Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets.

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/261ad4/comparative_analys) has announced the addition of the "Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets" report to their offering.

Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense Price Competition in High Volume Markets, which provides insights regarding the comparative analysis of marketed drugs based on safety, efficacy, cost of therapy and total sales revenue. The report also delves deep into the descriptions of every marketed drug, discussing their safety, efficacy, cost of therapy and clinical studies.

Patent Expiries will Intensify the Competition among Generic Players

A patent offers the patentee a monopoly of market exclusivity, and ensures returns on research investments in the absence of competition, therefore encouraging research into novel treatment options.

Patent Expiry of Marketed Drugs in Major Indications, The US, 2011 Note: US - United States, RA - Rheumatoid Arthritis, NSCLC - Non-Small Cell Lung Cancer, PAH - Pulmonary Arterial Hypertension, COPD - Chronic Obstructive Pulmonary Disease, NHL - Non-Hodgkin Lymphoma, GERD - Gastroesophageal Reflux Disease

In dyslipidemia, Lipitor is the world's biggest selling statin drug, with revenue of $11,434m in 2009. It was approved by the US FDA (United States Food and Drug Administration) in 1996. More than half of the antidyslipidemic market is commanded by Lipitor, which is a gold standard therapy. On January 6, 2009, the US Patent and Trademark office reissued a patent to Lipitor that will expire in June 2011. Apotex and Teva are seeking US FDA approval to sell generic versions of Lipitor, and were sued by Pfizer in 2008.

Read more inside Comparative Analysis of Marketed Drugs in Major Indications

For more information visit http://www.researchandmarkets.com/research/261ad4/comparative_analys
COPYRIGHT 2011 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Article Type:Clinical report
Date:Sep 14, 2011
Words:341
Previous Article:Research and Markets: Pediatric Cancer - Pipeline Review, H2 2011.
Next Article:Research and Markets: Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising...
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters